Form D · Biotechnology
Applied Proteomics, Inc.
San Diego, CA · CIK 0001548525
Offering snapshot reported Sep 25, 2013 · SEC filing
- Reported sold
- $27.9M Offering amount: $27.9M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 8, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2013 | Initial | $27,863,715 | No comparison | 7 | SEC filing |
| Apr 27, 2012 | Initial | $22,499,993 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-203489
Series C Preferred Stock
Source: Form D, filed Sep 25, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Abrutyn | Director, Executive |
| David Agus | Director |
| James Blair | Director |
| Daniel Hillis | Director |
| Erik Holmlin | Director |
| Peter Klemm | Director, Executive |
| Kok Thay Lim | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3545 John Hopkins Ct., Suite 150
San Diego, CA, 92121
San Diego, CA, 92121